Annovis to Host Patients’ Live Forum on February 27, 2025
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces a live webcast Patients' Forum scheduled for February 27, 2025, at 4:30 PM EST. CEO Maria Maccecchini, Ph.D., will lead the session, addressing questions from patients, caregivers, and families.
The forum will provide updates on several key areas including:
- Ongoing Phase 3 Alzheimer's disease trial
- Plans for Phase 3 Parkinson's disease study
- Open Label Extension studies
- Patient communication strategies
The event will feature a presentation of recent achievements followed by a Q&A session. Participants can submit questions in advance to clinicaltrials@annovisbio.com. While open to all, the forum is specifically designed for patients, families, and caregivers, demonstrating Annovis's commitment to transparency and patient-centered communication.
Annovis Bio (NYSE: ANVS), una compagnia farmaceutica in fase clinica focalizzata sulle malattie neurodegenerative, annuncia un webcast dal vivo Forum dei Pazienti programmato per 27 febbraio 2025, alle 16:30 EST. Il CEO Maria Maccecchini, Ph.D., guiderà la sessione, rispondendo alle domande di pazienti, caregiver e famiglie.
Il forum fornirà aggiornamenti su diverse aree chiave, tra cui:
- Studio clinico di Fase 3 sulla malattia di Alzheimer
- Piani per lo studio di Fase 3 sulla malattia di Parkinson
- Studi di estensione a etichetta aperta
- Strategie di comunicazione con i pazienti
L'evento presenterà una panoramica dei risultati recenti seguita da una sessione di domande e risposte. I partecipanti possono inviare domande in anticipo a clinicaltrials@annovisbio.com. Sebbene aperto a tutti, il forum è progettato specificamente per pazienti, famiglie e caregiver, dimostrando l'impegno di Annovis per la trasparenza e la comunicazione incentrata sul paziente.
Annovis Bio (NYSE: ANVS), una compañía farmacéutica en etapa clínica centrada en enfermedades neurodegenerativas, anuncia una transmisión en vivo Foro de Pacientes programada para 27 de febrero de 2025, a las 4:30 PM EST. La CEO Maria Maccecchini, Ph.D., dirigirá la sesión, respondiendo preguntas de pacientes, cuidadores y familias.
El foro proporcionará actualizaciones sobre varias áreas clave, incluyendo:
- Ensayo clínico en Fase 3 sobre la enfermedad de Alzheimer
- Planes para el estudio en Fase 3 sobre la enfermedad de Parkinson
- Estudios de extensión a etiqueta abierta
- Estrategias de comunicación con los pacientes
El evento contará con una presentación de logros recientes seguida de una sesión de preguntas y respuestas. Los participantes pueden enviar preguntas con anticipación a clinicaltrials@annovisbio.com. Aunque está abierto a todos, el foro está diseñado específicamente para pacientes, familias y cuidadores, demostrando el compromiso de Annovis con la transparencia y la comunicación centrada en el paciente.
Annovis Bio (NYSE: ANVS), 신경퇴행성 질환에 초점을 맞춘 임상 단계의 약물 플랫폼 회사가 환자 포럼을 2025년 2월 27일 오후 4시 30분 EST에 생중계할 예정이라고 발표했습니다. CEO인 Maria Maccecchini 박사가 세션을 이끌며 환자, 보호자 및 가족의 질문에 답변할 것입니다.
이번 포럼에서는 다음과 같은 여러 주요 분야에 대한 업데이트가 제공됩니다:
- 진행 중인 알츠하이머병 3상 시험
- 파킨슨병 3상 연구 계획
- 오픈 레이블 연장 연구
- 환자 커뮤니케이션 전략
행사는 최근 성과에 대한 발표와 Q&A 세션이 이어집니다. 참가자는 clinicaltrials@annovisbio.com으로 사전에 질문을 제출할 수 있습니다. 모든 사람에게 열려 있지만, 포럼은 환자, 가족 및 보호자를 위해 특별히 설계되어 있으며, Annovis의 투명성 및 환자 중심 커뮤니케이션에 대한 의지를 보여줍니다.
Annovis Bio (NYSE: ANVS), une entreprise de plateforme pharmaceutique en phase clinique axée sur les maladies neurodégénératives, annonce un webinaire en direct Forum des Patients prévu pour 27 février 2025 à 16h30 EST. La PDG Maria Maccecchini, Ph.D., animera la session, répondant aux questions des patients, des aidants et des familles.
Le forum fournira des mises à jour sur plusieurs domaines clés, notamment:
- Essai clinique de Phase 3 sur la maladie d'Alzheimer
- Plans pour l'étude de Phase 3 sur la maladie de Parkinson
- Études d'extension à étiquette ouverte
- Stratégies de communication avec les patients
L'événement comportera une présentation des réalisations récentes suivie d'une session de questions et réponses. Les participants peuvent soumettre des questions à l'avance à clinicaltrials@annovisbio.com. Bien que ouvert à tous, le forum est spécifiquement conçu pour les patients, les familles et les aidants, démontrant l'engagement d'Annovis envers la transparence et la communication centrée sur le patient.
Annovis Bio (NYSE: ANVS), ein Unternehmen in der klinischen Phase, das sich auf neurodegenerative Erkrankungen konzentriert, kündigt ein Live-Webcast Patientenforum an, das für 27. Februar 2025 um 16:30 Uhr EST geplant ist. CEO Maria Maccecchini, Ph.D., wird die Sitzung leiten und Fragen von Patienten, Pflegekräften und Familien beantworten.
Das Forum wird Updates zu mehreren wichtigen Bereichen bereitstellen, darunter:
- Aktuelle Phase-3-Studie zur Alzheimer-Krankheit
- Pläne für die Phase-3-Studie zur Parkinson-Krankheit
- Offene Verlängerungsstudien
- Strategien zur Patientenkommunikation
Die Veranstaltung umfasst eine Präsentation der jüngsten Erfolge, gefolgt von einer Q&A-Session. Teilnehmer können im Voraus Fragen an clinicaltrials@annovisbio.com senden. Obwohl es für alle offen ist, ist das Forum speziell für Patienten, Familien und Pflegekräfte konzipiert und zeigt das Engagement von Annovis für Transparenz und patientenorientierte Kommunikation.
- None.
- None.
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families about the Company’s clinical trials and future plans.
Webcast Details
- Event: Annovis Patients’ Forum: Your Questions Answered
- Date: February 27, 2025
- Time: 4:30 PM EST
- Registration: Click here to register
During the webcast, Dr. Maccecchini will provide updates on the ongoing Phase 3 AD trial, plans for the Phase 3 PD and Open Label Extension studies, and patient communication strategies. The webcast will include a short presentation highlighting recent achievements followed by a Q&A session. Attendees are encouraged to submit their questions in advance to clinicaltrials@annovisbio.com.
This event is open to all but is specifically designed for patients, families, and caregivers. Annovis regularly receives questions from current and prospective patients, and this forum aims to address as many as possible while providing a clear update on our work. Patients are at the heart of our mission, and we remain committed to transparency with our community.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements relate to the Company’s clinical trials, including patient enrollment, the efficacy and safety of Buntanetap, and expected outcomes. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
ir@annovisbio.com
FAQ
When is Annovis Bio (ANVS) hosting its Patients' Forum in 2025?
What clinical trials will be discussed at the ANVS February 2025 forum?
How can patients submit questions for the ANVS February 2025 forum?
What neurodegenerative diseases is Annovis Bio (ANVS) developing treatments for?
Who will be presenting at the ANVS Patients' Forum in February 2025?
